Lung cancer in HIV-infected patients in the combination antiretroviral treatment era

Translational Lung Cancer Research

Volumn 4, Issue 6, 2015, Pages 678-688

  Moltó, José ^a,b   Moran, Teresa ^a,b   Sirera, Guillem ^a,b   Clotet, Bonaventura ^a,b,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

Author keywords

Antiretroviral treatment; HIV infection; Lung cancer; Non AIDS defining cancers (NADCs)

Indexed keywords

EID: 84960118290     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2015.08.10     Document Type: Review

References (74)

1. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:425-32.
2. Deeken JF, Tjen-A-Looi, Rudeck MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012;55:1228-35.
3. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753-62.
4. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.
5. Hessol NA, Martínez-Maza O, Levine AM, et al. Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS 2015;29:1183-93.
6. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trend in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-54.
7. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006;24:1383-8.
8. Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007;21:207-13.
9. Shiels MS, Cole SR, Kirk GD, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009;52:611-22.
10. Herida M, May-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447-53.
11. Clifford GM, Lise M, Franceschi S, et al. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012;106:447-52.
12. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003;17:371-5.
13. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011:53;1130-9.
14. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012;26:1017-25.
15. Wright S, Lu X, Peterlin BM. Human immunodeficiency virus type 1 tat directs transcription through alteration sites within the mouse c-myc gene. J Mol Biol 1994;243:568-73.
16. Amini S, Khalili K, Sawaya BE. Effect of HIV-1 Vpr on cell cycle regulators. DNA Cell Biol 2004;23:249-60.
17. Li CJ, Wang C, Friedman DJ, et al. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1995;92:5461-4.
18. Altavilla G, Caputo A, Lanfredi M, et al. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 2000;157:1081-9.
19. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk of lung cancer, independent of smoking. Clin Infect Dis 2007;45:103-10.
20. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl cancer Inst 2011;103:1112-22.
21. Dubrow R, Silvenberg MJ, Park LS, et al. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012;24:506-16.
22. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
23. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDHANRS CO4): a prospective cohort study. Lancet Oncol 2009;10:1152-9.
24. Mbulaiteye SM, Biggar RJ, Goedert JJ, et al. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003;32:527-33.
25. Shebl FM, Engels EA, Goedert JJ, et al. Pulmonary infections and risk of lung cancer among persons with AIDS. J Acquir Immune Defic Syndr 2010;55:375-9.
26. Lavolé A, Wislez M, Antoine M, et al. Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 2006;51:1-11.
27. Pakkala S, Ramalingman SS. Lung cancer in HIV-positive patients. J Thorac Oncol 2010;5:1864-71.
28. Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIVinfected individuals. AIDS 2013;27:459-68.
29. Worm SW, Bower M, Reiss P, et al. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infect Dis 2013;13:471.
30. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 2000;88:563-9.
31. Lavole A, Massiani MA, Wislez M, et al. Lung cancer in HIV-infected patients in the era of HAART: a case control study focusing on prognostic factors of survival. Lung Cancer 2003;41:S3-14.
32. Alshafie MT, Donaldson B, Oluwole SF. Human immunodeficiency virus and lung cancer. Br J Surg 1997;84:1068-71.
33. Spano JP, Massiani MA, Bentata M, et al. Lung cancer in patients with HIV Infection and review of the literature. Med Oncol 2004;21:109-15.
34. Lavolé A, Chouaid C, Baudrin L, et al. Effect of highly active antiretroviral therapy on survival of HIV-infected patients with non-small-cell lung cancer. Lung Cancer 2009;65:345-50.
35. Bearz A, Vaccher E, Martellotta F, et al. Lung cancer in HIV patients: the GICAT experience. Eur Rev Med Pharmacol Sci 2014;18:500-8.
36. Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005;39:293-9.
37. Marcus JL, Chao C, Leyden WA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev 2015;24:1167-73.
38. Rengan R, Mitra N, Liao K, et al. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a populationbased study. Lancet Oncol 2012;13:1203-9.
39. Hakimian R, Fang H, Thomas L, et al. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2007;2:268-72.
40. Navarro JT, Ribera JM, Oriol A, et al. Favourable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma. Leuk Lymphoma 2002;43:1837-42.
41. Torres HA, Rallapalli V, Saxena A, et al. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect 2014;20:O672-9.
42. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
43. Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis 2014;59:106-14.
44. Beumer JH, Venkataramanan R, Rudek MA. Pharmacotherapy in cancer patients with HIV/AIDS. Clin Pharmacol Ther 2014;95:370-2.
45. Silverberg MJ, Neuhaus J, Boer M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007;21:1957-63.
46. DeVita VT, Lawrence TS, Rosenberg SA, et al., editors. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 8th Edition. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2008:385-548.
47. Chabner BA, Lynch TJ, Longo DL, et al., editors. Harrison's Manual of Oncology. New York: McGraw-Hill Companies Inc., 2008.
48. National Comprehensive Cancer Network guidelines for Non-Small-Cell Lung Cancer Management. Available online: www.nccn.org/professionals/physician_gls/PDF/ nscl.pdf
49. Okuma Y, Hosomi Y, Imamura A. Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus. Onco Targets Ther 2015;8:111-5.
50. Erickson TM, Koeppe JR, Miller YE, et al. Brochioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making. J Thorac Oncol 2008;3:1353-5.
51. Okuma Y, Tanura J, Kamiryo H, et al. A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection. J Cancer Res Clin Oncol 2015;141:1669-78.
52. King JR, Wynn H, Brundage R, et al. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 2004;43:291-310.
53. Bower M, Powels T, Stebbing J, et al. Potential antiretroviral drug interactions with cyclophosphamide, doxirrubicin, and etoposide. J Clin Oncol 2005;23:1328-9.
54. Levêque D, Santucci R, Pavillet J, et al. Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine. Pharm World Sci 2009;31:619-21.
55. Moltó J, Rajoli R, Back D, et al. Physiologically based pharmacokinetic model to predict drug-drug interaction in patients receiving antiretroviral and antineoplastic therapies. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Threrapy. Alexandria, VA, May 2015.
56. Sharma M, Saravolatz LD. Rilpivirine: a new nonnucleoside reverse transcriptase inhibitor. J Antimicrob Chemother 2013;68:250-6.
57. Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013;52:981-94.
58. Liedtke MD, Tomlin CR, Lockhart SM, et al. Long-term efficacy and safety of raltegravir in the management of HIV infection. Infect Drug Resist 2014;7:73-84.
59. Shah BM, Schafer JJ, Priano J, et al. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2013;33:1107-16.
60. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011;365:395-409.
61. Sigel K, Wisnivesky J, Shahrir, et al. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS 2014:28:1007-14.
62. Hulbert A, Hooker CM, Keruly JC, et al. Prospective CT screening for lung cancer in a high-risk population: HIVpositive smokers. J Thorac Oncol 2014;9:752-9.
63. Persad GC, Little RF, Grady C. Including persons with HIV infection and cancer in clinical trials. J Clin Oncol 2008;26:1027-32.
64. National Cancer Institute Cancer Therapy Evaluation Program: Guidelines regarding the inclusion of cancer survivors and HIV-positive individuals on clinical trials. Bethesda, MD, National Cancer Institute, 2006.
65. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-91.
66. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma:An Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol 2004;22:1491-500.
67. Coghill AE, Shiels MS, Suneja G, et al. Elevated Cancer-Specific Mortality among HIV-infected patients in the United States. J Clin Oncol 2015;33:2376-83.
68. Vandenhende MA, Roussillon C, Henard S, et al. Cancerrelated causes of death among HIV-infected patients in France in 2010: evolution since 2000. Plos One 2015;10:e0129550-12.
69. Velu V, Shetty RD, Larsson M, et al. Role of PD-1 coinhibitory pathways in HIV infection and potential therapeutic options. Retrovirology 2015;12:14.
70. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
71. Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015;10:e0130142.
72. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35.
73. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004-12.
74. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:abstr LBA109.